Suscriptores   Asóciese  
Textos Completos Autorizados
PERSPECTIVAS ACTUALES SOBRE UN ESQUEMA DE DOSIFICACION SEMANAL DE DOCETAXEL PARA EL CANCER DE MAMA

v-estudie-lo-mejor.gif
Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
EL TRATAMIENTO CON TRASTUZUMAB DERUXTECÁN ES SEGURO EN PACIENTES CON CÁNCER DE MAMA MESTASTÁSICO
ESMO Open 8(4):1-9
Difundido en siicsalud: 17 abr 2024
EXPRESIÓN BAJA DE HER2 EN EL CÁNCER DE MAMA TEMPRANO RE+
Anticancer Research 43(10):1-11
Difundido en siicsalud: 11 abr 2024

PERSPECTIVAS ACTUALES SOBRE UN ESQUEMA DE DOSIFICACION SEMANAL DE DOCETAXEL PARA EL CANCER DE MAMA

(especial para SIIC © Derechos reservados)
El esquema de dosificación semanal de docetaxel, en lugar del trisemanal, podría evitar los efectos adversos graves en el tratamiento del cáncer de mama avanzado.
kuroi9.jpg Autor:
Katsumasa Kuroi
Columnista Experto de SIIC

Institución:
Department of Surgery Showa University Toyousu Hospital

Artículos publicados por Katsumasa Kuroi
Coautor
Masakazu Toi* 
MD, PhD. Division of Clinical Trial and Research, Metropolitan Cancer Center and Infectious Diesase Center, Komagome Hospital*
Recepción del artículo
17 de Mayo, 2005 		Aprobación
13 de Junio, 2005
Primera edición
3 de Febrero, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

PERSPECTIVAS ACTUALES SOBRE UN ESQUEMA DE DOSIFICACION SEMANAL DE DOCETAXEL PARA EL CANCER DE MAMA

Resumen
El docetaxel es un agente quimioterapéutico muy efectivo que se emplea para el tratamiento paliativo del cáncer de mama avanzado o metastásico y también como quimioterapia adyuvante o neoadyuvante. Existen diversos estudios publicados sobre el uso de docetaxel en forma semanal en lugar de la administración trisemanal. En esos estudios se demostró que el uso de docetaxel semanal es un régimen viable y efectivo en el contexto de los cuidados paliativos y que se puede administrar combinado con trastuzumab. La dosificación semanal es el esquema de elección tanto para los facultativos como para las pacientes, en particular en aquellas con puntajes de desempeño desfavorables o que son mayores, y porque la administración semanal también reduce el riesgo de efectos colaterales agudos como la mielosupresión. No obstante, la dosificación semanal con docetaxel puede presentar efectos tóxicos colaterales acumulativos que limitan el tratamiento, entre ellos figuran fatiga, astenia, cambios ungueales, retención de líquidos y lagrimeo excesivo. La información acerca del papel de la dosificación semanal como adyuvante o neoadyuvante es todavía insuficiente así como lo es la combinación con otros tratamientos como la terapia radiante y los agentes citotóxicos.

Palabras clave
Docetaxel, esquema semanal, toxicidad, respuesta, cáncer de mama


Artículo completo
(castellano)
Extensión:  +/-12.5 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

A CURRENT PERSPECTIVE ON THE USE OF A WEEKLY DOCETAXEL DOSING SCHEDULE IN BREAST CANCER

Abstract
Docetaxel is a highly effective chemotherapeutic agent that is used for palliation of advanced or metastatic breast cancer as well as for adjuvant or neoadjuvant chemotherapy. There have been several reported studies on the use of docetaxel on a weekly rather than tri-weekly basis. In these studies, weekly docetaxel was found to be a feasible and effective regimen in the palliative-care setting and it can be administered in combination with trastuzumab. Weekly dosing is the schedule of choice for both physicians and patients, particularly for patients who have poor performance status scores or who are elderly, and weekly dosing also reduces the risk of acute adverse events such as myelosuppression. However, weekly dosing with docetaxel may have cumulative treatment-limiting toxic side effects such as fatigue, asthenia, nail changes, fluid retention, and hyperlacrimation. There is still insufficient information about the role of weekly dosing in the adjuvant or neoadjuvant setting and in combination with other treatment modalities such as radiation and cytotoxic agents.

Key words
Docetaxel, weekly schedule, toxicity, response, breast cancer


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Oncología
Relacionadas: Farmacología, Medicina Farmacéutica, Medicina Interna, Obstetricia y Ginecología



Comprar este artículo
Extensión: 12.5 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 2004; 9 Suppl 2:24-32.
  2. Bonneterre J, Spielman M, Guastalla JP, et al. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer 1999; 35:1431-9.
  3. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996; 73:210-6.
  4. Fumoleau P, Chevallier B, Kerbrat P, et al. A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTC. Ann Oncol 1996; 7:165-71.
  5. O’Brien ME, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in the community setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol 1999; 10:205-10.
  6. Salminen E, Bergman M, Huhtala S, et al. Docetaxel: standard recommended dose of 100 mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. J Clin Oncol 1999; 17:1127-31.
  7. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212-9.
  8. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999; 26:28-31.
  9. Bunnell C. Current perspectives for treatment of breast cancer. Breast Cancer 2000; 7:380-8.
  10. Baselga J,Tabernero JM. Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 2001; 6 Suppl 3:26-9.
  11. Löffler TM. Is there a place for “dose-dense” weekly schedules of the taxoids Semin Oncol 1998; 25:32-4.
  12. Kuroi K, Bando H, Saji S, et al. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer 2003; 10:10-4.
  13. Wildiers H,Paridaens R. Taxanes in elderly breast cancer patients. Cancer Treat Rev 2004; 30:333-42.
  14. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353-61.
  15. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 2001; 6 Suppl 3:30-5.
  16. Gasparini G. Metronomic scheduling: the future of chemotherapy Lancet Oncol 2001; 2:733-40.
  17. Hahnfeldt P, Folkman J,Hlatky L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 2003; 220:545-54.
  18. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86.
  19. Kerbel RS,Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423-36.
  20. Hanahan D, Bergers G,Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105:1045-7.
  21. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus Paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002; 11:103-18.
  22. Hainsworth JD, Burris HAI, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998; 16:2164-8.
  23. Hainsworth JD, Burris HAI,Greco FA. Weekly administration of docetaxel (Taxotere): summary of clinical data. Semin Oncol 1999; 26:19-24.
  24. Briasoulis E, Karavasilis V, Anastasopoulos D, et al. Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration. Ann Oncol 1999; 10:701-6.
  25. Kouroussis C, Agelaki S, Mavroudis D, et al. A dose escalation study of weekly docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2000; 46:488-92.
  26. Hainsworth JD, Burris HAI, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 2001; 19:3500-5.
  27. Kuroi K, Bando H, Nagai S, et al. Efficacy of weekly docetaxel therapy for advanced or recurrent breast cancer. Jpn J Cancer Chemother 2001; 28:797-802.
  28. Kuroi K, Bando H, Saji S, et al. Protracted administration of weekly docetaxel in metastatic breast cancer. Oncol Rep 2003; 10:1479-84.
  29. Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotere) in patients with metastatic breast cancer. Ann Oncol 2001; 12:1393-8.
  30. Aihara T, Kim Y,Takatsuka Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2002; 13:286-92.
  31. Maisano R, Mare M, Zavettieri M, et al. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer Anticancer Res 2003; 23:1923-6.
  32. Mey U, Gorschluter M, Ziske C, et al. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 2003; 14:233-8.
  33. Ramos M, Gonzalez-Ageitos A, Amenedo M, et al. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 2003; 15:192-7.
  34. D’Hondt R, Paridaens R, Wildiers H, et al. Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 2004; 15:341-6.
  35. Raff JP, Rajdev L, Malik U, et al. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer 2004; 4:420-7.
  36. Stemmler J, Mair W, Stauch M, et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 2005; 68:71-8.
  37. Ballot J, McDonnell D,Crown J. Successful treatment of thrombocytopenia due to marrow metastases of breast cancer with weekly docetaxel. J Natl Cancer Inst 2003; 95:831-2.
  38. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15:1358-65.
  39. Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 2001; 21:1301-5.
  40. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-8.
  41. Tedesco KL, Thor AD, Johnson DH, et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 2004; 22:1071-7.
  42. Gennari A, Guarneri V, Landucci E, et al. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer. Clin Breast Cancer 2002; 3:346-52.
  43. Frasci G, Comella P, D’Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG). Ann Oncol 2000; 11:367-71.
  44. Wenzel C, Locker GJ, Pluschnig U, et al. Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 2002; 50:155-9.
  45. Morabito A, Gattuso D, Stani SC, et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 2004; 86:249-57.
  46. Cals L, Nouyrigat P, Valenza B, et al. Weekly combination of docetaxel and vinorelbine in metastatic breast cancer: a phase I/II study. Oncology 2004; 67:257-61.
  47. Mackey JR, Tonkin KS, Koski SL, et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin Breast Cancer 2004; 5:287-92.
  48. O’Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23.
  49. Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004; 15:1274-83.
  50. Estévez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 2003; 9:686-92.
  51. Wenzel C, Hussian D, Bartsch R, et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004; 130:400-4.
  52. Hurley J, Reis I, Silva O, et al. Weekly Docetaxel/Carboplatin as Primary Systemic Therapy for HER2-Negative Locally Advanced Breast Cancer. Clin Breast Cancer 2005; 5:447-54.
  53. Miller KD, Soule SE, Calley C, et al. Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel; primary chemotherapy as Biomarker Discovery Laboratory. Breast Cancer Res Treat 2005; 89:187-97.
  54. Dang CT, D’Andrea GM, Moynahan ME, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004; 10:5754-61.
  55. Kim Y, Takatsuka Y, Gotoh K, et al. Pharmacological study of weekly docetaxel in patients with metastatic breast cancer. Jpn J Cancer Chemother 1999; 26:1437-41.
  56. Slaviero KA, Clarke SJ, McLachlan AJ, et al. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004; 57:44-53.
  57. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149-55.
  58. Brink HM,Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol 1995; 90:1-6.
  59. Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotereo) in patients with metastatic breast cancer. Ann Oncol 2001; 12:1393-8.
  60. Hofer S, Hunziker S, Tornillo L, et al. Fatal herpes simplex virus hepatitis complicating chemotherapy with weekly docetaxel. Ann Oncol 2003; 14:340.
  61. Massacesi C, Marcucci F, Rocchi MB, et al. Factors predicting docetaxel-related toxicity: experience at a single institution. J Chemother. 2004;16:86-93.
  62. Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer 2005; 5:455-7.
  63. Esmaeli B, Valero V, Ahmadi MA, et al. Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001; 108:994-5.
  64. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol 2002; 13:218-21.
  65. Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120:1180-2.
  66. Moisidis C,Mobus V. Erythema multiforme major following docetaxel. Arch Gynecol Obstet 2004.
  67. Hussain S, Anderson DN, Salvatti ME, et al. Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer 2000; 88:2367-71.
  68. Piraccini BM,Tosti A. Drug-induced nail disorders: incidence, management and prognosis. Drug Saf 1999; 21:187-201.
  69. Wasner G, Hilpert F, Baron R, et al. Clinical picture: nail changes secondary to docetaxel. Lancet 2001; 357:910.
  70. Wasner G, Hilpert F, Schattschneider J, et al. Docetaxel-induced nail changes--a neurogenic mechanism: a case report. J Neurooncol 2002; 58:167-74.
  71. Stemmler HJ, Kenngotte S, Diepolder H, et al. Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 2002; 13:978-81.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

 English title
 Abstract
 Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
Artículos relacionadosMás relacionadosAtículos relacionados
TRATAMIENTOS DE FISIOTERAPIA MÁS EFICACES PARA LA REHABILITACIÓN DEL SÍNDROME DE LA RED AXILAR
Supportive Care in Cancer 31(257):1-14
Difundido en siicsalud: 22 feb 2024
INCIDENCIA ELEVADA DE RADIODERMATITIS EN MUJERES CON CÁNCER DE MAMA
Anais Brasileiros de Dermatologia 99(1):57-65
Difundido en siicsalud: 11 abr 2024
ESTILO DE VIDA Y RIESGO DE CÁNCER DE MAMA EN MUJERES
Advances In Nutrition 14(4):685-709
Difundido en siicsalud: 1 feb 2024
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517